Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21534104 | 0.94 | GLP1R (0.48) | GLP1RSIRT2NOD1FOLH1 | |
| SCHEMBL21032736 | 0.87 | FOLH1 (0.51) | FOLH1ALB | |
| SCHEMBL19975584 | 0.85 | FOLH1 (0.36) | NOD1FOLH1 | |
| SCHEMBL19970336 | 0.85 | FOLH1 (0.36) | NOD1FOLH1 | |
| SCHEMBL19975587 | 0.82 | GNPAT (0.37) | NOD1FOLH1 | |
| SCHEMBL21534085 | 0.81 | FOLH1 (0.35) | NOD1FOLH1 | |
| SCHEMBL21031586 | 0.80 | FOLH1 (0.47) | FOLH1 | |
| SCHEMBL21032263 | 0.76 | FOLH1 (0.60) | SIRT2FOLH1MMP1MMP3 | |
| SCHEMBL23452088 | 0.75 | NOD1 (0.61) | GLP1RNOD1FOLH1ALBCASP2 | |
| SCHEMBL13057100 | 0.75 | NOD1 (0.61) | GLP1RNOD1FOLH1ALBCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617662-B2 | Autophagy activation-induced compound for improving skin inflammation for aging | INCOSPHARM CORPORATION (KR) | 2020-04-14 | — | — | US | disclosed |
| US-20190160033-A1 | NOVEL AUTOPHAGY ACTIVATION-INDUCED COMPOUND FOR IMPROVING SKIN INFLAMMATION FOR AGING | INCOSPHARM CORPORATION (KR) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617662-B2 | Autophagy activation-induced compound for improving skin inflammation for aging | TFEB, ATG7, BECN1 | GLP1R 730/4885SIRT2 43/4885NOD1 783/4885 |
| US-20190160033-A1 | NOVEL AUTOPHAGY ACTIVATION-INDUCED COMPOUND FOR IMPROVING SKIN INFLAMMATION FOR AGING | TFEB, ATG7, BECN1 | GLP1R 857/4885SIRT2 47/4885NOD1 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.